Skip to content
The Nexus
DossierENTITY

gene-editing therapies

Coverage of gene-editing therapies in the Nexus archive.

Earliest in view: Jul 10 · 13:35 UTCMost recent: Jul 10 · 13:35 UTC
Co-mentioned in this coverage
Rocheorganization1Huntington’s gene-silencingtopic1ARPA-Horganization1Medicareorganization1obesity drug discount programtopic1
Recent coverage
  • HEALTHJul 10 · 13:35 UTCSTAT NEWS
    STAT+: Roche ends Huntington’s gene-silencing programs

    Roche has discontinued two Huntington’s gene-silencing drugs due to disappointing data. ARPA-H announced a $160 million initiative to accelerate gene-editing therapies for rare diseases. Drugmakers are promoting Medicare’s new obesity drug discount program.

gene-editing therapies · Dossier · The Nexus